A. F. Dico

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

E. Borsi, E. Zamagni, M. Cavo, 2014, Experimental cell research.

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

G. Martinelli, E. Borsi, E. Zamagni, 2014, Oncotarget.

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

E. Borsi, E. Zamagni, C. Terragna, 2023, Clinical and experimental medicine.